(Q36676374)

15 August 2017

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World? (English)

1 reference

15 August 2017

16

Pierre Côté

0 references

Sahar Saeed

object named as

Sahar Saeed

1

0 references

Michael John Gill

object named as

M John Gill

8

0 references

Julio Montaner

23

object named as

Julio Montaner

1 reference

15 August 2017

5

Neora Pick

1 reference

15 August 2017

3

Sharon L Walmsley

1 reference

15 August 2017

26

Anita Rachlis

1 reference

15 August 2017

29

Joseph Mark Tyndall

1 reference

15 August 2017

19

Shariq Haider

1 reference

15 August 2017

28

Roger Sandre

1 reference

15 August 2017

Erin C Strumpf

2

1 reference

15 August 2017

Kathleen Rollet-Kurhajec

4

1 reference

15 August 2017

Valerie Martel-Laferrière

6

1 reference

15 August 2017

Mark Hull

7

1 reference

15 August 2017

Joseph Cox

9

1 reference

15 August 2017

Curtis Cooper

10

1 reference

15 August 2017

Marina B Klein

11

1 reference

15 August 2017

Canadian Co-Infection Cohort Study

12

1 reference

15 August 2017

Jeff Cohen

13

1 reference

15 August 2017

Brian Conway

14

1 reference

15 August 2017

Curtis Cooper

15

1 reference

15 August 2017

Pierre Côté

16

1 reference

15 August 2017

Joseph Cox

17

1 reference

15 August 2017

John Gill

18

1 reference

15 August 2017

Marianne Harris

20

1 reference

15 August 2017

David Haase

21

1 reference

15 August 2017

Mark Hull

22

1 reference

15 August 2017

Erica Moodie

24

1 reference

15 August 2017

Neora Pick

25

1 reference

15 August 2017

Danielle Rouleau

27

1 reference

15 August 2017

Marie-Louise Vachon

30

1 reference

15 August 2017

David Wong

32

1 reference

15 August 2017

language of work or name

English

0 references

publication date

6 January 2016

1 reference

Clinical Infectious Diseases

15 August 2017

1 reference

15 August 2017

62

1 reference

15 August 2017

7

1 reference

15 August 2017

919-926

1 reference

Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfected with HIV: a prospective cohort study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Factors influencing adherence in Hepatitis-C infected patients: a systematic review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Sofosbuvir for previously untreated chronic hepatitis C infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

The changing epidemiology of liver disease in HIV patients.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Treatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Hepatitis C treatment for injection drug users: a review of the available evidence

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

The challenge of hepatitis C in the HIV-infected person

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4787608

Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FCID%2FCIV1222

Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FCID%2FCIV1222

Estimating treatment effects using observational data

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26743093

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/CID/CIV1222

1 reference

15 August 2017

1 reference

15 August 2017

1 reference